Arcus Biosciences (RCUS) Long-Term Investments (2017 - 2026)

Arcus Biosciences' Long-Term Investments history runs 10 years deep, the most recent figure standing at $54.0 million for Q1 2026.

• In Q1 2026, Long-Term Investments rose 575.0% year-over-year to $54.0 million; the TTM figure through Mar 2026 stood at $54.0 million (up 575.0% YoY), while the FY2025 annual figure was $29.0 million, up 107.14% from the prior year.
• Long-Term Investments was $54.0 million for Q1 2026 at Arcus Biosciences, up from $29.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $151.0 million in Q3 2023 to a low of $2.0 million in Q3 2024.
• Historically, Long-Term Investments has averaged $70.6 million across 5 years, with a median of $80.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Long-Term Investments tumbled 98.68% in 2024, then jumped 575.0% in 2026.
• A 5-year view of Long-Term Investments shows it stood at $129.0 million in 2022, then decreased by 17.05% to $107.0 million in 2023, then plunged by 86.92% to $14.0 million in 2024, then surged by 107.14% to $29.0 million in 2025, then surged by 86.21% to $54.0 million in 2026.
• The last three Long-Term Investments figures came in at $54.0 million (Q1 2026), $29.0 million (Q4 2025), and $10.0 million (Q3 2025), per Business Quant data.